To the best of our knowledge, this is the first study to evaluate H19 polymorphism and its associations with the clinicopathologic presentations of prostate cancer among Taiwanese men, especially focused on patients with relatively low iPSA levels. The gene discussed is H19; the disease is prostate cancer.